Multiple Alloantibodies after Transfusion in an Infant Treated with Infliximab
- 15 November 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (20), 2092-2093
- https://doi.org/10.1056/nejmc070741
Abstract
Infliximab (Remicade) is a humanized mouse monoclonal antibody that blocks tumor necrosis factor α.1 It down-regulates type 1 helper T-cell (Th1) immune responses and increases type 2 helper T-cell (Th2) responses, thereby favoring antibody production.2 There are many reports of autoantibody formation after the administration of infliximab, including a case of autoimmune hemolytic anemia.1 We report on a 10-month-old boy who received infliximab for systemic-onset juvenile rheumatoid arthritis and who had a severe hemolytic transfusion reaction.Keywords
This publication has 6 references indexed in Scilit:
- Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cellsTransfusion, 2006
- Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritisArthritis & Rheumatism, 2005
- Autoantibody profile in rheumatoid arthritis during long-term infliximab treatmentArthritis Research & Therapy, 2004
- Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort studyGastroenterology, 2003
- Early primary immune response against erythrocytes: a case reportTransfusion Medicine, 2003
- Presence of the red cell alloantibody anti‐E in an 11‐week‐old infantTransfusion, 1992